September 22, 2026
AnaptysBio posted a smaller loss and higher sales than expected for the second quarter, then its shares fell 4.1 percent.
What happened
AnaptysBio reported an adjusted loss of $0.11 per share against an estimate of a $0.46 loss. Sales came in at $27.488 million, beating the $21.675 million forecast. The stock dropped 4.1 percent on the day, a move larger than 76 percent of its daily swings over the past three years.
Why it matters
The results show the company losing far less money than Wall Street thought while producing more revenue, which ordinarily supports a biotech name by easing concerns about cash burn and validating its commercial path. The selloff despite a clean beat suggests traders had already priced in even better news, or something else in the report spooked them.
The case against
A 4.1 percent decline on a day this size means sellers overwhelmed any relief from the beat. The market may have picked up on soft guidance, a write-down, a trial update, or simply a wider risk-off rotation that shrugged off strong numbers in a single small-cap name.
What settles it
Whether AnaptysBio gave quarterly or full-year guidance that fell short of the whisper number, or disclosed a pipeline setback that would explain selling on an earnings beat.